You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: β-blockers for hypertension increase risk of new onset diabetes

https://doi.org/10.1136/ebm.13.2.50

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    S Bangalore

    Dr S Bangalore, Columbia University College of Physicians and Surgeons, New York, NY, USA; sbangalo@chpnet.org

    REVIEW PROCESS

    Question:

    in patients with hypertension, do β-blockers increase risk of new onset diabetes?

    Search methods:

    Medline, PubMed, and EMBASE/Excerpta Medica (to March 2007).

    Study selection and assessment:

    randomised controlled trials (RCTs) that were published in English in peer-reviewed journals, compared β-blockers with placebo or other antihypertensive agents as first line therapy for hypertension, and reported incidence of new onset diabetes at ⩾1 year. 12 RCTs (n = 94 492, mean age 50–76 y, 33–100% men) met the selection criteria: 2 RCTs (n = 16 372) compared β-blockers with placebo, 5 RCTs (n = 17 860) compared β-blockers with thiazide diuretics, and 7 RCTs (n = 65 765) compared β-blockers (with or without diuretics) with non-diuretic antihypertensive agents (angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], or calcium …

    View Full Text

    Footnotes

    • Source of funding: not stated.